MedPath

HOKKAIDO UNIVERSITY

HOKKAIDO UNIVERSITY logo
🇯🇵Japan
Ownership
Private
Established
1876-01-01
Employees
501
Market Cap
-
Website
http://www.hokudai.ac.jp

Clinical Trials

173

Active:0
Completed:108

Trial Phases

4 Phases

Phase 1:1
Phase 2:2
Phase 4:1
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (171 trials with phase data)• Click on a phase to view related trials

Not Applicable
167 (97.7%)
Phase 2
2 (1.2%)
Phase 1
1 (0.6%)
Phase 4
1 (0.6%)
No trials found

News

Gut Microbiome Metabolite HYA Shows Promise for Blood Sugar Management in Type 1 Diabetes

A novel study reveals that HYA, a gut microbiome-derived metabolite, effectively reduces post-meal blood sugar spikes in type 1 diabetes model rats through multiple mechanisms.

Ensitrelvir Shows 67% Reduction in COVID-19 Risk as First Effective Post-Exposure Prophylaxis in Phase 3 Trial

Shionogi's SCORPIO-PEP Phase 3 trial demonstrated ensitrelvir reduces COVID-19 risk by 67% in exposed household contacts, making it the first oral antiviral to successfully prevent COVID-19 after exposure.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.